Log in

NASDAQ:TECHBIO-TECHNE Stock Price, Forecast & News

+1.60 (+0.61 %)
(As of 08/13/2020 04:00 PM ET)
Today's Range
Now: $263.42
50-Day Range
MA: $269.02
52-Week Range
Now: $263.42
Volume103,300 shs
Average Volume231,176 shs
Market Capitalization$10.07 billion
P/E Ratio45.50
Dividend Yield0.49%
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. It has strategic partnership with NanoString Technologies. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.3Dividend Strength: 0.8Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.52 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
Current SymbolNASDAQ:TECH



Sales & Book Value

Annual Sales$738.69 million
Cash Flow$5.92 per share
Book Value$36.13 per share


Net Income$229.30 million


Market Cap$10.07 billion
Next Earnings Date11/3/2020 (Estimated)
+1.60 (+0.61 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions

How has BIO-TECHNE's stock been impacted by Coronavirus?

BIO-TECHNE's stock was trading at $180.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TECH shares have increased by 45.9% and is now trading at $263.42.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of BIO-TECHNE?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for BIO-TECHNE

When is BIO-TECHNE's next earnings date?

BIO-TECHNE is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for BIO-TECHNE

How were BIO-TECHNE's earnings last quarter?

BIO-TECHNE Corp (NASDAQ:TECH) posted its quarterly earnings data on Tuesday, August, 4th. The biotechnology company reported $1.00 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.43. The biotechnology company had revenue of $175.83 million for the quarter, compared to analysts' expectations of $165.70 million. BIO-TECHNE had a net margin of 31.04% and a return on equity of 11.94%. The business's quarterly revenue was down 8.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.25 EPS.
View BIO-TECHNE's earnings history

How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?

BIO-TECHNE announced a quarterly dividend on Tuesday, February 4th. Investors of record on Friday, February 14th will be given a dividend of $0.32 per share on Friday, February 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.49%. The ex-dividend date of this dividend is Thursday, February 13th.
View BIO-TECHNE's dividend history

What price target have analysts set for TECH?

9 brokers have issued 1 year target prices for BIO-TECHNE's shares. Their forecasts range from $220.00 to $328.00. On average, they anticipate BIO-TECHNE's share price to reach $268.25 in the next twelve months. This suggests a possible upside of 1.8% from the stock's current price.
View analysts' price targets for BIO-TECHNE

Has BIO-TECHNE been receiving favorable news coverage?

Headlines about TECH stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. BIO-TECHNE earned a coverage optimism score of -2.4 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about BIO-TECHNE

Are investors shorting BIO-TECHNE?

BIO-TECHNE saw a decrease in short interest in May. As of May 15th, there was short interest totaling 619,700 shares, a decrease of 22.5% from the April 30th total of 800,100 shares. Based on an average daily trading volume, of 298,400 shares, the days-to-cover ratio is currently 2.1 days. Approximately 1.6% of the company's stock are short sold.
View BIO-TECHNE's Short Interest

Who are some of BIO-TECHNE's key competitors?

What other stocks do shareholders of BIO-TECHNE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include NVIDIA (NVDA), Paychex (PAYX), Cisco Systems (CSCO), Gilead Sciences (GILD), AbbVie (ABBV), Veeva Systems (VEEV), Broadcom (AVGO), Amgen (AMGN), IBM (IBM) and Abbott Laboratories (ABT).

Who are BIO-TECHNE's key executives?

BIO-TECHNE's management team includes the following people:
  • Mr. Charles R. Kummeth, CEO, Pres & Director (Age 59)
  • Mr. James T. Hippel, Sr. VP of Fin. & CFO (Age 48)
  • Ms. Brenda S. Furlow, Gen. Counsel, Sec. & Chief Compliance Officer (Age 61)
  • Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 58)
  • Mr. Gerry Andros, VP of Sales and Marketing

What is BIO-TECHNE's stock symbol?

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

Who are BIO-TECHNE's major shareholders?

BIO-TECHNE's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Jackson Square Partners LLC (2.61%), Bank of New York Mellon Corp (1.21%), First Trust Advisors LP (1.05%), Riverbridge Partners LLC (1.01%), Conestoga Capital Advisors LLC (0.95%) and New York State Common Retirement Fund (0.80%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends for BIO-TECHNE

Which major investors are selling BIO-TECHNE stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Candriam Luxembourg S.C.A., Thrivent Financial for Lutherans, Sumitomo Mitsui Trust Holdings Inc., Summit Creek Advisors LLC, Tygh Capital Management Inc., New York State Common Retirement Fund, and Goldman Sachs Group Inc.. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, Norman David Eansor, Robert V Baumgartner, and Roeland Nusse.
View insider buying and selling activity for BIO-TECHNE

Which major investors are buying BIO-TECHNE stock?

TECH stock was purchased by a variety of institutional investors in the last quarter, including Prudential Financial Inc., First Trust Advisors LP, Obermeyer Wood Investment Counsel Lllp, Nordea Investment Management AB, State of Tennessee Treasury Department, WINTON GROUP Ltd, Bank of New York Mellon Corp, and Natixis Advisors L.P.. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth, and Robert V Baumgartner.
View insider buying and selling activity for BIO-TECHNE

How do I buy shares of BIO-TECHNE?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BIO-TECHNE's stock price today?

One share of TECH stock can currently be purchased for approximately $263.42.

How big of a company is BIO-TECHNE?

BIO-TECHNE has a market capitalization of $10.07 billion and generates $738.69 million in revenue each year. BIO-TECHNE employs 2,250 workers across the globe.

What is BIO-TECHNE's official website?

The official website for BIO-TECHNE is www.techne-corp.com.

How can I contact BIO-TECHNE?

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.